Special Issue "Canine Cancer Immunology and Immunotherapeutics in 2022"
A special issue of Veterinary Sciences (ISSN 2306-7381). This special issue belongs to the section "Veterinary Microbiology, Parasitology and Immunology".
Deadline for manuscript submissions: 30 November 2022 | Viewed by 1555
Interests: molecular pathogenesis of feline immunodeficiency virus infection; vaccine development in animal models for HIV-1 AIDS; use of cytokines and TLR ligands as vaccine adjuvants; tumor immunology in companion animal cancer
Special Issues, Collections and Topics in MDPI journals
Interests: developing new immunotherapies to treat cancer; cancer vaccines; repurposed immunotherapy drugs; checkpoint targeted immunotherapies
Interests: comparative cancer immunology; immunotherapy; canine T-lymphocyte subsets; tumor associated macrophages; tumor microenvironment; metastasis; osteosarcoma
Reports over the past decade have shown that agents that activate the immune system by blocking specific anti-inflammatory check points, as well as engineered T cells, have proven to be effective in certain human cancer patient populations. Based on similar strategies and in some cases more novel approaches, canine-specific immunotherapeutics have been recently described and more are in the development pipeline. Canine immunotherapeutics in current investigations include monoclonal antibodies that target immune checkpoints and cancer-specific antigens, oncolytic viruses, nonspecific immunodulators including cytokines and ligands for pattern recognition receptors (PPRs), cancer vaccines, and T cell therapy, such as chimeric antigen receptor (CAR) T cells. Such therapeutic modalities carry the potential to significantly impact treatment protocols for certain canine cancers as well as human cancer in the future and therefore present an area of focus for clinical canine cancer research.
This Special Issue aims to report the current progress in the characterization of canine cancer immune profiles and the development of canine cancer immunotherapeutic strategies and protocols. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: development of diagnostic agents for the recognition of canine cancer-related immune markers, characterization of canine cancer-related immune profiles particularly to guide selection of patients for specific immunotherapeutics, and development and testing of canine cancer immunotherapeutics.
We look forward to receiving your contributions.
Dr. Ellen E. Sparger
Prof. Dr. Steven Dow
Dr. Sita Withers
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Veterinary Sciences is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- canine cancer
- cancer immunotherapeutics
- animal models
- checkpoint inhibitors
- engineered T cells
- cancer vaccines
- cancer-related immune profiles
- immune modulation in cancer
- immunotherapy toxicities
- One Health
- One Medicine
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Contributing Authors: Clara Martín-Carrasco, Pablo Delgado-Bonet, Beatriz Davinia Tomeo-Martín, Claudia de la Riva, Paula Palau-Concejo, Noemí del Castillo, Javier García-Castro and Ana Judith Perisé-Barrios